Pharmacokinetic Characterization of KR-67500, a Novel 11β-HSD1 Inhibitor
Yakhak Hoeji · 2015
DOI: 10.17480/psk.2015.59.2.59 ↗Kurz gefasst
Fachartikel in der Zeitschrift Yakhak Hoeji, 2015. Verfasst von So Hee Im. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
KR-67500, trans-4-(2-(4-methyl-1,1-dioxido-6-(2,4,6-trichlorophenyl)-1,2,6-thiadiazinan-2-yl)acetamido)ada- mantane-1-carboxamide, is a novel 11β-HSD1 inhibitor with its therapeutic effects of its anti-diabetic, anti-adipogenic and anti-osteoporotic activity. This study was performed to evaluate in vitro and in vivo pharmacokinetic properties of KR-67500 as a new drug candidate. KR-67500 was stable and highly bound to proteins in rat plasma. The microsomal stabilities of KR- 67500 in human and rat liver were high. The inhibitory effect of KR-67500 for five cytochrome P450 enzymes was low. Pre- clinical pharmacokinetic studies have been carried out with intravenous or oral administrations of KR-67500 (10 mg/kg) to male rats and monkey. KR-67500 showed low clearance (0.68 l/h/kg) and high oral bioavailability (102%) in male rats. These results suggest that KR-67500 has good drug-like pharmacokinetic properties with a low first-pass effect and high bio- availability for an oral therapeutic agent of diabetes and osteoporosis.
Zitieren
APA
Im, S. H. (2015). Pharmacokinetic Characterization of KR-67500, a Novel 11β-HSD1 Inhibitor. Yakhak Hoeji. https://doi.org/10.17480/psk.2015.59.2.59
Vancouver
Im SH. Pharmacokinetic Characterization of KR-67500, a Novel 11β-HSD1 Inhibitor. Yakhak Hoeji. 2015. doi:10.17480/psk.2015.59.2.59
BibTeX
@article{Im2015,
author = {Im, So Hee},
title = {Pharmacokinetic Characterization of KR-67500, a Novel 11β-HSD1 Inhibitor},
journal = {Yakhak Hoeji},
year = {2015},
doi = {10.17480/psk.2015.59.2.59}
}
EUVIMED